1. Home
  2. FURY vs CGTX Comparison

FURY vs CGTX Comparison

Compare FURY & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fury Gold Mines Limited

FURY

Fury Gold Mines Limited

HOLD

Current Price

$0.53

Market Cap

103.6M

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$0.92

Market Cap

102.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FURY
CGTX
Founded
2008
2007
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.6M
102.9M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
FURY
CGTX
Price
$0.53
$0.92
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$1.70
$3.33
AVG Volume (30 Days)
126.0K
1.6M
Earning Date
08-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.79
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.46
$0.55
52 Week High
$1.02
$3.83

Technical Indicators

Market Signals
Indicator
FURY
CGTX
Relative Strength Index (RSI) 49.20 37.66
Support Level $0.51 $0.55
Resistance Level $0.57 $1.19
Average True Range (ATR) 0.03 0.08
MACD 0.00 -0.01
Stochastic Oscillator 29.05 6.33

Price Performance

Historical Comparison
FURY
CGTX

About FURY Fury Gold Mines Limited

Fury Gold Mines Ltd is a Canadian-focused high-grade gold exploration company. The company's projects are strategically positioned in two prolific mining regions: the Eeyou Istchee James Bay Region of Quebec and the Kitikmeot Region in Nunavut. Fury Gold's project portfolio comprises the Committee Bay gold project in Nunavut, and the Eau Claire gold, Sakami gold, Elmer East gold and lithium, and Eleonore South gold projects in Quebec. Additionally, it also owns interests in the Kipawa rare earths project and has full ownership of the Zeus heavy rare earths project, both located in the Temiscamingue region of Quebec. The company operates in two reportable segments: Quebec and Nunavut.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: